Pharmacovigilance China 2011 July 4, 2011

Building a harmonised pharmacovigilance framework

Following the very successful Pharmacovigilance Asia conference, PharmaIQ continues the cutting-edge research into the pharmacovigilance field, particularly into the massive and unique market of China.

China has quickly become one of the largest pharmaceutical markets and R&D centers for international pharmaceutical companies due to its huge population and their increased healthcare awareness. In addition, with more and more clinical trial activities taking place in China, building and reinforcing a harmonised pharmacovigilance framework is becoming more critical to reduce drug risks and improve patient safety.

Compared to their counterparts in the US and Europe, pharmacogivilance regulators and pactitioners in China still have a long way to go. Faced with a unique set of regulations, multinational pharmaceutical companies are balancing between their internal practice while complying with the local regulations. They also yearn for a harmonised pharmacovigilance framework to help them working more efficiently.

Pharmacovigilance China 2011 is an unique learning platform that will bring together regulators as well as practitioners from the industry to discuss the ongoing pressing issues faced in drug safety, risk management, timeline constraints and varied regulatory standards. A featured panel of experts from the US and Europe will also be invited to provide you with key learning opportunities.
Key Benefits for Attending Pharmacovigilance China 2011

• Join the one and only conference platform for both pharmacovigliance regulators and industry practitioners
• Hear from an excellent panel of mixed speakers from both Asia and developed countries including the US and Europe
• Learn about pharmacovigilance and drug safety in China today, as well as the challenges and implications ahead to clinical trials and marketing
• Discus best practices for both post-market and clinical stage pharmacovigilance
• Analyse different processes and methods for ADR case evaluation
• Exploring ways of developing and reinforcing a harmanised pharmacovigilance framework

What Delegates Say About our Past Events:

The very first event tailored on PV on a great Asian perspective!
– PV Associate, Korea Otsuka

Simple enough to a beginner, complex enough for the experienced. Brilliant!
– Senior Safety Officer, GSK

Very interesting with experienced key players
– Head of Regional Center Pharmacovigilance, Boehringer Ingelheim

Very well organised conference. Attendees mix was nice – including industry and regulators! Well done!
– Head, Lifesciences EU & APAC, Cognizant

A great opportunity to network with peers in the region!
– Associate Manager, Product Surveillance, Bausch & Lomb

This conference offers the opportunity for those working in pharmacovigilance to share expertise and learn about best practice and challenge the way they do things.
– Pharmacovigliance Manager, MSD